iRhythm Technologies Inc. directors and executives harmed the medical device company by concealing shortcomings in its heart monitor’s performance, including transmission issues that led to two deaths, an investor alleges.
The board members and officers failed to disclose that the wearable Zio AT device for diagnosing and monitoring cardiac arrhythmias wasn’t capable of real-time, continuous transmission to doctors; wasn’t suitable for high-risk patients; required registration by the patient before beginning transmission; and capped data transmission after a certain number of arrhythmias, Jennifer Purcell-Jones says.
She filed her derivative suit on behalf of iRhythm on Thursday in the US District Court ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.